Sarepta Therapeutics (SRPT) FY2018 results: revenue $301 million, up 94.7% on the year
Sarepta Therapeutics, Inc. (SRPT) reported revenue of $301 million for fiscal 2018, the year ended 31 December 2018, up 94.7% on the year before. Net income was -$362 million, and diluted earnings per share $-5.46. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2019.
Revenue
$301 million
+94.7% on the year
FY2014FY2018
Operating margin
-114.1%
-111.0% a year earlier
FY2014FY2018
Net income
-$362 million
FY2014FY2018
Diluted EPS
-$5.46
FY2014FY2018
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Revenue
301
155
5.4
+94.7%
Cost of revenue
n/a
n/a
0.1
Gross profit
n/a
n/a
5.3
Gross margin
n/a
n/a
97.6%
Research and development
402
167
188
+141.0%
Selling, general and administrative
208
123
83.7
+69.3%
Operating income
-344
-172
-267
Operating margin
-114.1%
-111.0%
-4920.3%
Interest expense
33.7
5.8
1.9
+481.1%
Pre-tax income
-363
-48.6
-267
Income tax
-0.7
2.1
n/a
Net income
-362
-50.7
-267
Net margin
-120.2%
-32.8%
-4930.2%
Diluted EPS
-$5.46
-$0.86
-$5.49
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Operating cash flow
-389
-232
-246
Capital expenditure
61.2
12.0
5.3
+409.6%
Free cash flow
-450
-244
-251
Free cash flow margin
-149.4%
-157.8%
-4633.1%
Cash from investing
-370
-179
-90.2
Cash from financing
530
888
378
-40.3%
Depreciation and amortisation
12.2
8.1
5.6
+51.3%
Share-based compensation
50.1
30.5
30.0
+64.5%
Diluted shares, weighted
66m
59m
49m
+12.6%
Shares outstanding at period end
71m
65m
55m
+9.7%
Balance sheet
$ million
FY2018
FY2017
FY2016
On the year
Last 8 years
Shareholders' equity
1,032
789
337
+30.8%
Debt
421
431
17.7
-2.4%
Other liabilities
189
87.7
69.7
+115.8%
Total liabilities and equity
1,642
1,308
424
+25.5%
Fixed assets
97.0
43.2
37.8
+124.8%
Intangible assets
11.6
14.4
8.1
-19.4%
Investments
803
489
195
+64.1%
Cash and equivalents
371
600
122
-38.2%
Receivables
49.0
29.5
5.2
+66.4%
Inventory
125
83.6
12.8
+50.0%
Other assets
185
48.3
42.3
+283.0%
Total assets
1,642
1,308
424
+25.5%
10-K for the year ended 31 December 2018, filed 28 February 2019: the filing.